Can Sound Help Fight Cancer? Inside SonALAsense's Innovative Approach

Every breakthrough in cancer treatment begins with someone asking a simple question: What if there were a better way?

At SonALAsense, that question has led researchers to explore the possibility whether focused ultrasound could help activate cancer treatment directly inside a tumor. The investigational approach, known as sonodynamic therapy, aims to target cancer cells while sparing healthy tissue, offering a new avenue of research for some of the most difficult-to-treat cancers.

The need for innovation is especially urgent in childhood brain cancer. For children diagnosed with diffuse intrinsic pontine glioma (DIPG), one of the most aggressive paediatric brain tumors, treatment options remain extremely limited. Around 300 children in the United States are diagnosed with this rare and aggressive brain cancer each year, most between the ages of five and nine. The tumor develops deep within the brainstem, which is an area responsible for vital functions such as breathing, swallowing and movement. As such, it cannot be safely removed through surgery. While radiation therapy can temporarily slow the disease, the benefits are often short-lived, and there are currently no approved treatments that can stop the cancer from progressing.

Most cancer treatments work by attacking rapidly dividing cells throughout the body. While these therapies can be effective, they often damage healthy tissue as well, leading to significant side effects. Even after intensive treatment, some cancers return. SonALAsense believes there may be another way. The company's investigational treatment is based on sonodynamic therapy (SDT), a non-invasive approach that combines a drug with focused ultrasound.

The process begins with an intravenous medicine derived from a naturally occurring nutrient. On its own, the drug remains inactive. However, it is converted into a light- and sound-sensitive compound that accumulates in much higher amounts inside cancer cells than in healthy tissue. Doctors then apply focused ultrasound to the tumour. The ultrasound activates the compound only where it has accumulated, creating a highly localized therapeutic effect designed to damage cancer cells while minimizing harm to surrounding healthy tissue.

Developing new treatments for childhood brain cancers is uniquely challenging. The brain is one of the most delicate organs in the body, and many medicines struggle to cross the blood-brain barrier, a protective network that prevents harmful substances from reaching the brain but also limits the effectiveness of many cancer drugs.

For children with DIPG, the challenge is even greater. The tumour's location within the brainstem makes surgery impossible, leaving families with very few options beyond radiation therapy. That is why researchers are increasingly exploring new technologies capable of targeting tumors more precisely while sparing healthy tissue.

Early laboratory and clinical studies suggest that sonodynamic therapy may have potential in aggressive brain tumors, including DIPG. Parents who have participated in early clinical studies have described seeing meaningful improvements in their children's quality of life following treatment. While these early experiences are encouraging, much larger clinical trials are needed before researchers can determine whether the therapy is safe and effective enough for widespread use.

Like many promising childhood cancer therapies, SonALAsense now faces one of the greatest challenges in medical innovation: funding. Developing a new treatment does not end with a scientific breakthrough. Before a therapy can become available to patients, it must progress through carefully designed clinical trials to establish its safety and effectiveness and meet rigorous regulatory standards.

For rare childhood cancers such as DIPG, this journey is particularly difficult. Because relatively few children are diagnosed each year, recruiting enough participants for clinical trials takes time, while the costs of manufacturing specialised medicines, supplying treatment devices and conducting multi-centre studies continue to grow.

SonALAsense's next milestone is a pivotal clinical trial, the final stage required before seeking FDA approval. The company is working to raise US$7 million to support the study, helping ensure that this promising therapy does not become another casualty of the so-called "Valley of Death," which is the grim nickname of the funding gap where many innovative treatments stall before reaching the patients they were designed to help. Without sustained investment, potentially life-changing therapies may never move beyond the laboratory.

Scientific breakthroughs rarely happen in isolation. They depend not only on researchers and clinicians, but also on families, donors, investors and communities willing to support innovation long before success is guaranteed. That is the mission behind Music Beats Cancer's upcoming Thumbs Up for A Cure Hamptons campaign. Bringing together families affected by childhood cancer, biotech entrepreneurs, clinicians, biopharma leaders, artists, philanthropists and community supporters, the initiative helps bridge the gap between promising scientific discoveries and the clinical trials needed to bring them to patients.

For children diagnosed with devastating diseases like DIPG, every new treatment begins as an idea that requires years of research, careful testing and sustained support. SonALAsense's work is one example of how researchers are challenging the status quo in childhood cancer care. While there is still much work ahead, innovations like sonodynamic therapy offer hope that future generations of children may one day have treatment options that are not only more effective, but also less invasive and gentler on their growing bodies.

This article was written in collaboration with Music Beats Cancer, a non-profit organization focused on fundraising for cancer research.